After simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up.

Size: px
Start display at page:

Download "After simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up."

Transcription

1 New Medical Device Company Addresses Two Very High Demand Markets with its Proprietary Products. Trader Tracks likes this company as they provide reasonably priced equipment and testing while medical costs are skyrocketing. Miraculins Inc. has two hot products for medical testing While the company s opening market focus is targeted for North America, they have signed a new $90 million sales and distribution agreement in China for one of its two propritary products offering non-invasive testing for diabetes. After simple testing that only takes minutes people with elevated test results are then recommended to see their physicians for follow-up. A technical chart double price bottom is bullish. It gets even better when those price bases are further spread out in June and November as we see on the following chart. The stock price on Wednesday January 7, 2014 is C$.24. Our technical price forecast for the shares during 2015 is C$.83 In our view this is not a trading stock for now. Trader Tracks recommends a buy and hold with a time cycle of at least 6-12 months and perhaps longer. This company, based upon offered products, is addressing huge mass international markets that could have a long way to go in both price and earnings.

2 One year chart for MOM shows a solid trading range from C$.10 to C$.45. The medical device company is offering investors a chance to enter and hold for what we believe could be excellent gains. Miraculins at a Glance Miraculins is a biotechnology company that acquires develops and commercializes new, non-invasive diagnostic and risk assessment tests to aid physicians in the earlier diagnosis of disease. The company s lead technology programs the Scout DS Diabetes Screen and the PreVu Skin Cholesterol Test are point-of-care tests that screen for risk of diabetes and coronary artery disease respectively, without needles, blood draw, fasting or waiting. Patients with elevated test results are then recommended to see their physicians for follow-up. The Scout DS is a ground-breaking, non-invasive diabetes-screening device that uses visible light to fluoresce, detect and measure biomarkers present in the skin associated with pre-diabetes and type 2 diabetes and takes only 90 seconds. The PreVu Non-Invasive Skin Cholesterol Point-of-Care (POC) Test measures cholesterol in the skin as a new risk marker for coronary artery disease, without requiring needles, blood draw or fasting... in less than 5 minutes Both of these technologies are totally non-invasive and user-friendly, characteristics that can encourage individuals to get screened early and often for risk of pre-diabetes and type 2 diabetes - now being referred to by experts as the fastest growing disease in history - and risk of coronary artery disease, for which diabetes is also a major risk factor.

3 On August 14, 2014, the Company announced that it had executed a definitive agreement for the sale and distribution of Scout DS diabetes screening devices into China with Catalyn Medical Technologies Limited, a privately-owned and Hong Kong based medical device import Company. It was also announced that Cachet Pharmaceutical Co., Ltd. had been co-appointed as the exclusive distributor of the Scout DS devices in Mainland China by Miraculins and Catalyn. The agreement allows for the sale and distribution of up to $90 Million USD in Scout DS Diabetes Screening Devices in Mainland China, over the length of the 5-year agreement term. Miraculins, Inc. a Canadian biotechnology company (MOM) has 20,228,000 shares outstanding with a market cap of 10 million. The 52 week high was posted on January 7, The 52 week low was posted on June 9, The average price for 50 days is C$.15 and for 200-days is C$.16. Volumes for 50-day average 62,036 and for 200-days 45,549. Miraculins Completes Amendment to 2013 Scout DS Asset Purchase Agreement with VeraLight December 23, 2014 company website WINNIPEG, Manitoba December 23, Miraculins Inc. (TSX-V:MOM) (the Company ), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces that it has executed an amendment (the Amendment ) with VeraLight, Inc. ( VeraLight ) to the asset purchase agreement dated June 28, 2013 between Miraculins and VeraLight (the APA ), wherein Miraculins acquired all of the relevant assets relating to VeraLight s Scout DS non-invasive diabetes screening technology. The Amendment eliminates the

4 majority of the Company s remaining obligations and terminates the obligation to issue equity to VeraLight under APA. In connection with the Amendment, the Company has made a one-time payment of CDN $500,000 to VeraLight. In addition to the one-time payment, the Company has issued 1,000,000 new common share purchase warrants (the Warrants ) to VeraLight at an exercise price of CDN $0.25 per share with a term expiring on the fifth anniversary after issuance. Of these, 450,000 of the Warrants will vest immediately and the remaining 550,000 Warrants will vest upon the earlier of (i) 12 months from the date of issuance, or (ii) a Liquidity Event (as defined below). No common shares or warrants have previously been issued to VeraLight, and on the closing of the Agreement, VeraLight will have no right to receive common shares of the Company other than the Warrants described above. With the recent announcement of our USD$90 Million sales and distribution agreement for Scout DS in China, and our strong belief in the technology s growing potential, we entered into discussions with VeraLight to amend the asset purchase agreement, said Christopher J. Moreau, President and Chief Executive Officer for Miraculins Inc. In addition to terminating our obligation to provide Veralight with equity under the APA, the Amendment has eliminated the Company s obligations related to spending on ScoutDS related activities, adherence to certain manufacturing commitments and reporting obligations related to Scout DS, the appointment of a VeraLight nominee to the Company s Board, and also terminates VeraLight s first ranking security on all APA assets. company website Scout DS and PreVu Market Potential Miraculins believes that the key to bringing these numbers down is earlier screening bringing diabetes and heart disease through the introduction of non-invasive, user-friendly and rapid screening technologies that will encourage individuals to take a few minutes out of their busy days, in convenient settings, to get tested and educated about their potential risk. The goal of the Miraculins screening technologies is to provide patients at risk with an early distance warning and to serve as a tipping point for individuals to take real-time action and follow-up with their healthcare providers for immediate, effective and ongoing management of their conditions, whatever the stage. Screening allows for faster, earlier testing and greater patient turnaround, as well as a pain free alternative that doesn t require needles, fasting, blood work, or waiting. Widespread access to these new and innovative technologies which are also highly mobile, affordable, and cost-effective - could significantly increase early screenings worldwide, leading to positive impacts for patients, physicians, and the healthcare economy overall. The Company s commercialization strategy is global in vision and includes leasing and selling its Scout DS and PreVu medical devices and consumables to hospitals, clinics and physician s offices; retail testing through stand-alone kiosks in pharmacies/grocery chains; and workplace health screenings through companies of various sizes in both the private and public sectors, as well as through government employers. Pharmacies and grocery chains are expected to be quite responsive, for instance, in that the average prediabetic and diabetic patient can generate up to $800 and $3,000 per year in revenue, respectively. Workplace screenings can also additionally help companies better manage their employees health and wellness, realize lower disability and medical claims, and enhance efficiencies which are significant motivations to participation in screening programs as well. In the long term, the Company also intends to

5 build its case for government/private insurance reimbursement in multiple markets, and believes that CPT codes already exist in the U.S. to cover the Scout DS test in physician s offices, on procurement of FDA clearance for the device. -website Some very beneficial key points we see for this company and its products Miraculins is addressing two very high demand healthcare needs, with their screening tests locked into a long term growth mode as a result. Those being diabetes risk screening in the USA alone there are 30 million type-2 diabetics (1 in 4 don t know it) and 86 million pre-diabetics (9 in 10 don t know it) - and screening for risk of coronary artery disease, which is the number one killer of American men and women and is the leading cause of premature, permanent disability in the United States labor force. I can see serious growth for these products as medical plans in Canada and America are going into overload with limited personnel and sky rocketing expenses. These devices enable quick tests in doctor s offices and other accessible channels that can be performed every 1-3 years towards ongoing risk assessment and to assist with earlier disease detection. In a recent conference call with the CEO we learned of the strong clinical data behind the devices underscoring their utilities, which in our view is paramount. As the news of these products is more widespread and recognized, the increased visibility will promote better global medical care and in our view, a boost for the shares. The Chinese agreement provides Miraculins with a gateway entry in Asian markets that might be larger in sales scope than North America. For Investor Relations: Telephone or ir@miraculins.com Miraculins Inc., Waverley Street, Winnipeg, Manitoba R3T 6C6 Telephone: Fax: info@miraculins.com Copyright by Wavelength Publishing LLC. No reproduction of this material is allowed without publisher permission.

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020

Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List

More information

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020

BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020 BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...

More information

Mexico Ostomy Drainage Bags Market Outlook to 2020

Mexico Ostomy Drainage Bags Market Outlook to 2020 Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...

More information

ASX Investor Presentation

ASX Investor Presentation ASX Investor Presentation Sydney, Australia Dr Peter Neustadt Executive Chairman and CEO November 2014 Copyright and registered trademark notice ASX Investor Presentation Page 0 Who we are SomnoMed Limited

More information

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance- Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-

More information

EU5 Bariatric Surgery Procedures Outlook to 2020

EU5 Bariatric Surgery Procedures Outlook to 2020 EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...

More information

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020

Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020 Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020

China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

Asia-Pacific Electrophysiology Market Outlook to 2020

Asia-Pacific Electrophysiology Market Outlook to 2020 Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...

More information

For personal use only

For personal use only Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development

More information

Malaria Initiative: Access

Malaria Initiative: Access Novartis Social Business Malaria Initiative: Access Improving affordability and availability of medicines Over the past decade, the Novartis Malaria Initiative has pioneered the pharmaceutical response

More information

Shareholder Presentation Annual Meeting 2018

Shareholder Presentation Annual Meeting 2018 Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)

More information

The Danish Medicines Agency s availability strategy

The Danish Medicines Agency s availability strategy låst DECEMBER 2016 The Danish Medicines Agency s availability strategy 2017 2021 Danish Medicines Agency, 2016 This publication may be freely quoted with appropriate acknowledgement of the source. Images

More information

The Value of Walgreens

The Value of Walgreens The Value of Walgreens How Walgreens improves employer health plans through access, quality and lower costs Why millions of patients choose Walgreens And your options to move forward with Walgreens Walgreens

More information

HeartSciences MyoVista High Sensitivity ECG Technology LAUNCH Key Messages and Q&A Updated: August 17, 2017

HeartSciences MyoVista High Sensitivity ECG Technology LAUNCH Key Messages and Q&A Updated: August 17, 2017 HeartSciences MyoVista High Sensitivity ECG Technology LAUNCH Key Messages and Q&A Updated: August 17, 2017 Key Messages Message 1: Diagnostic Gap Detection of Asymptomatic Patients Physicians do not have

More information

Cutanea Life Sciences, Inc. Comprehensive Compliance Program

Cutanea Life Sciences, Inc. Comprehensive Compliance Program Cutanea Life Sciences, Inc. Comprehensive Compliance Program Cutanea engages in research, development, manufacture and marketing of dermatology products, including commercialization of those products.

More information

Jefferies Healthcare Conference. June 2016

Jefferies Healthcare Conference. June 2016 Jefferies Healthcare Conference June 2016 Today s Speakers John Figueroa Chief Executive Officer Vic Breed Chief Financial Officer Joined Genoa in July 2014 Previously served the dual roles of CEO of Apria

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

China Interventional Cardiovascular Device Industry Report, Jan. 2011

China Interventional Cardiovascular Device Industry Report, Jan. 2011 China Interventional Cardiovascular Device Industry Report, 2010 Jan. 2011 This report analyzes the social, economic and policy environments, the overall operation, market competition and development trends

More information

January 30, 2018 Dow Wilson President and Chief Executive Officer

January 30, 2018 Dow Wilson President and Chief Executive Officer Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking

More information

Policy Options for the Regulation of Electronic Cigarettes

Policy Options for the Regulation of Electronic Cigarettes Policy Options for the Regulation of Electronic Cigarettes Consultation submission Your details This submission was completed by: Address: (name) Mark Forsyth (street/box number) 3 Queens Wharf (town/city)

More information

Noninvasive Glucose Monitors to 2022

Noninvasive Glucose Monitors to 2022 Noninvasive Glucose Monitors to 2022 Devices, Technologies, Players and Prospects Report Prospectus Greystone Research associates N o n i n v a s i v e G l u c o s e M o n i t o r s t o 2 0 2 2 Greystone

More information

Cannabis Regulation in Canada:

Cannabis Regulation in Canada: Cannabis Regulation in Canada: Where We Came From, Where We Are and What s Coming Next Jonathan Sherman Cassels Brock & Blackwell LLP Sherri Altshuler Aird & Berlis LLP Canada, In Brief Right Now... Legal

More information

Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage

Segment Coverage By Type By Age Group. Global Coverage Regional Coverage Country Coverage Global Cervical Cancer Diagnostics Market By Type (Pap Testing, HPV Testing, Colposcopy and Cervical Biopsies), By Age Group (35 years): Forecast to 2022 By Type - Pap Test, HPV Test,

More information

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile

Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile Tandem Diabetes Care, Inc. (TNDM) - Medical Equipment - Deals and Alliances Profile BioPortfolio has been marketing business

More information

2006 Annual Report. Anastomosis Made Simple

2006 Annual Report. Anastomosis Made Simple 2006 Annual Report R Anastomosis Made Simple Cardica designs and manufactures proprietary automated anastomosis systems used by surgeons to perform rapid, reliable and consistent connections, or anastomoses,

More information

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

VolitionRx Announces First Quarter 2016 Financial Results and Business Update May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused

More information

Institute of Medicine (IOM) Consensus Study on Accessible and Affordable Hearing Health Care for Adults

Institute of Medicine (IOM) Consensus Study on Accessible and Affordable Hearing Health Care for Adults Institute of Medicine (IOM) Consensus Study on Accessible and Affordable Hearing Health Care for Adults Hearing Loss Association of America Anna Gilmore Hall April 27, 2015 I got a hearing aid and it is

More information

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis

Submitted to the House Energy and Commerce Committee. Federal Efforts to Combat the Opioid Crisis STATEMENT FOR THE RECORD Submitted to the House Energy and Commerce Committee Federal Efforts to Combat the Opioid Crisis October 25, 2017 America s Health Insurance Plans 601 Pennsylvania Avenue, NW Suite

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

Russia Cardiac Assist Devices Market Outlook to 2021

Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 Russia Cardiac Assist Devices Market Outlook to 2021 BioPortfolio has been marketing business and market research reports from selected publishers for

More information

Noninvasive Glucose Monitors Devices, Technologies, Players and Prospects

Noninvasive Glucose Monitors Devices, Technologies, Players and Prospects Report Prospectus Noninvasive Glucose Monitors Devices, Technologies, Players and Prospects 1 Improving Diabetes Management For diabetes patients, glucose monitoring is a way of life, a several-times-per-day

More information

Halton Region. Business Conditions

Halton Region. Business Conditions Halton Region Business Conditions 2014 Message from Regional Chair Gary Carr Time and again, innovative business owners in Halton tell me that Halton is a great place to live and work because we offer

More information

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB

SAMPLE. Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to Reference Code: GDME0166BDB Syringes and Needles Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0166BDB Publication Date: January 2013 GlobalData. This report is a licensed product

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) December 21, 2016 Sumitomo Dainippon Pharma Co., Ltd. Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company) Sumitomo Dainippon Pharma Co., Ltd. (Head office: Osaka,

More information

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show

More information

Assessing private expenditures in HIV/AIDS: methods, tools, examples

Assessing private expenditures in HIV/AIDS: methods, tools, examples Assessing private expenditures in HIV/AIDS: methods, tools, examples Dr Ravi P. Rannan-Eliya Targeted programs financing and budgeting for HIV/AIDS Seminar Yalta Hotel, Yalta, Crimea, Ukraine 19 July 2007

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210

ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 ABSOLUTE NNN LEASE 19 Years Remaining 8815 Stagecoach Rd. Little Rock, AR 72210 Price- $6,330,275 Cap Rate-5.45% Absolute Net Lease with 19 Years Remaining on Initial Lease Term. Lease Guaranteed by Walgreen

More information

eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research eclinical Solutions Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research " Projected to grow at a CAGR of around 12%, eclinical solutions market is expected to witness significant

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

China Insulin Industry Report, Jan. 2011

China Insulin Industry Report, Jan. 2011 China Insulin Industry Report, 2010 Jan. 2011 This report analyzes the status, competition pattern and development direction of the insulin industry Focuses on the operation and development prospect of

More information

China Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011

China Oral Hypoglyceimic Agents (OHAs) Industry Report, Feb. 2011 China Oral Hypoglyceimic Agents (OHAs) Industry Report, 2010 Feb. 2011 This report Analyzes the status quo and prospect of Chinese OHAS Market. Related Products China Interventional Cardiovascular Device

More information

Annual Shareholders Meeting

Annual Shareholders Meeting Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking

More information

ASX Announcement 22 June 2017

ASX Announcement 22 June 2017 ASX Announcement 22 June 2017 Investment Conference Presentation Attached is the presentation given by ITL Health Group at the Gold Coast Investment Showcase 21-22 June 2017 ITL Health Group ITL is an

More information

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

CEO Operational Report. Annual General Meeting 23 October 2013

CEO Operational Report. Annual General Meeting 23 October 2013 CEO Operational Report Annual General Meeting 23 October 2013 Leading the Field Clinical Trials Axon Sports Cogstate Research COGNIGRAM Playing an integral role in cognition-related clinical trials Cutting

More information

Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595

Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595 Transparency Market Research Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019 Single User License: US $ 4595 Buy Now Request Sample

More information

Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice

Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice Donald G. Klepser, PhD, MBA Associate Professor University of Nebraska Medical Center Brian Bobby Rite Aid Vice President,

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

Pandemic Flu: Preplanning for an Outbreak

Pandemic Flu: Preplanning for an Outbreak Pandemic Flu: Preplanning for an Outbreak Presented to AACRAO Leta Finch Executive Director, Higher Education Practice Group Arthur J. Gallagher Risk Management Services, Inc. 2006 Arthur J. Gallagher

More information

Investment in MGC Pharmaceuticals

Investment in MGC Pharmaceuticals Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information

More information

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

RULES OF CONDUCT OF INSIDERS RESPECTING

RULES OF CONDUCT OF INSIDERS RESPECTING T RULES OF CONDUCT OF INSIDERS RESPECTING RADING O F SECURITIES OF TFI International lnc. Amended and restated July 2015 Executive Summary As an insider of TFI International Inc. ( TFI International )

More information

Korean Airlines Q Results

Korean Airlines Q Results Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell

More information

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( )

Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country ( ) Global HPV Vaccine Market: Analysis By End-User (Male, Female), By Age Group (Adolescents, Adults) - By Region, By Country (2017-2022) By Region- North America, Europe, APAC and RoW By Country - United

More information

The Dental Corporation Opportunity

The Dental Corporation Opportunity The Dental Corporation Opportunity for Practice Principals. It s the perfect professional collaboration. You focus on dentistry, we look after the paperwork. In recognition of what you, the Practice Principal,

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options

More information

Almirall grants Invida commercial rights for Aclidinium in Australia and New ZealandAlmirall????? (Invida)??????????? Aclidinium?????

Almirall grants Invida commercial rights for Aclidinium in Australia and New ZealandAlmirall????? (Invida)??????????? Aclidinium????? Almirall grants Invida commercial rights for Aclidinium in Australia and New ZealandAlmirall????? (Invida)??????????? Aclidinium????? Almirall licenses Aclidinium to Invida in Australia and New Zealand

More information

Mexico Milling Machine for Dental Clinics Industry 2016 Market Research Report

Mexico Milling Machine for Dental Clinics Industry 2016 Market Research Report Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Mexico Milling Machine for Dental Clinics Industry Market Research Report Mexico Milling Machine for Dental Clinics

More information

Itamar Medical. December Investors Presentation.

Itamar Medical. December Investors Presentation. Itamar Medical December 2017. Investors Presentation. Disclaimer Itamar Medical Ltd. (the "Company") is furnishing this presentation and any information given during this presentation, solely for the consideration

More information

Worldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015

Worldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015 Worldwide Nanotechnology Dental Implants-- Markets Reach $8.1 By 2015 LEXINGTON, Massachusetts (March 14, 2009) WinterGreen Research announces that it has a new study on Worldwide nanotechnology dental

More information

Chapter 1: Executive Summary

Chapter 1: Executive Summary Chapter 1: Executive Summary Definition, Scope, and Methodology Related Terms Functional Foods Nutraceuticals Foods for Special Dietary Use Condition-specific Nutritional Supplements Medical Foods Medical

More information

WALGREENS DRONE FOOTAGE AVAILABLE. Absolute NNN Lease Investment Opportunity. 758 N Ellington Parkway Lewisburg, TN

WALGREENS DRONE FOOTAGE AVAILABLE. Absolute NNN Lease Investment Opportunity. 758 N Ellington Parkway Lewisburg, TN WALGREENS 758 N Ellington Parkway Lewisburg, TN Absolute NNN Lease Investment Opportunity Click here to view drone footage of the property! DRONE FOOTAGE AVAILABLE STUART FRANKEL PRESIDENT NET LEASED DIVISION

More information

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement For immediate release April 28, 2005 Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement Dainippon Pharmaceutical Co., Ltd. Sumitomo Pharmaceuticals Co., Ltd. Dainippon Pharmaceutical

More information

Cannabis use carries significant health risks, especially for people who use it frequently and or/begin to use it at an early age.

Cannabis use carries significant health risks, especially for people who use it frequently and or/begin to use it at an early age. Background: The Centre for Addiction and Mental Health (CAMH) released recommendations for the Legalization of Marijuana (with restrictions and regulations) on October 8, 2014. Addiction Services of Thames

More information

Global Aspergillosis Drugs Market Professional Survey Report 2016

Global Aspergillosis Drugs Market Professional Survey Report 2016 Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018

SAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report

More information

Indonesia-Intensified Iodine Deficiency Control Project. Ministry of Health (MOH)/Ministry of Industry (MOI)

Indonesia-Intensified Iodine Deficiency Control Project. Ministry of Health (MOH)/Ministry of Industry (MOI) Project Name Region Sector Project ID Implementing Agency Report No. PIC2866 Indonesia-Intensified Iodine Deficiency Control Project East Asia and Pacific Population and Human Resources IDPA42450 Ministry

More information

ASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE

ASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE ASX ANNOUNCEMENT CELLMID CEO TO PRESENT AT WHOLESALE INVESTOR CONFERENCE SYDNEY, Tuesday, 20 November 2012: Cellmid Limited (ASX: CDY) CEO, Maria Halasz, will present today at the Wholesale Investor Conference,

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

NET LEASE INVESTMENT OFFERING RITE AID PHARMACY

NET LEASE INVESTMENT OFFERING RITE AID PHARMACY RITE AID PHARMACY 11702 Lorain Avenue Cleveland, OH 44111 TABLE OF CONTENTS TABLE OF CONTENTS I. Executive Profile Executive Summary Investment Highlights Property Overview II. Location Overview Photographs

More information

Sample Pages. Needlestick Safety Injection Devices Market, Copyright 2012 Banyan Wharf Consultants Ltd. Page 1

Sample Pages. Needlestick Safety Injection Devices Market, Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 Sample Pages Needlestick Safety Injection Devices Market, 2014-2024 Copyright 2012 Banyan Wharf Consultants Ltd. Page 1 This page is intentionally left blank Copyright 2014 Roots Analysis Private Ltd.

More information

FOR IMMEDIATE RELEASE: Media Alert:

FOR IMMEDIATE RELEASE: Media Alert: FOR IMMEDIATE RELEASE: Media Alert: 1-Source/AMP-RTI Unveils Design, application, system and product development of SGD For Aphasic Speech Pathology Segment for O Brien Technologies, Inc. Lenoir, NC &

More information

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review

H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review H. Lundbeck AS (LUN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports

More information

Hot Topics in Healthcare Osher Lifelong Learning Institute University of California at San Diego. October 17, 2017

Hot Topics in Healthcare Osher Lifelong Learning Institute University of California at San Diego. October 17, 2017 Hot Topics in Healthcare Osher Lifelong Learning Institute University of California at San Diego October 17, 2017 Format Notes Speakers present pro and con perspectives Goal is to inform..not have one

More information

Ultrasound Device Market - Industry Analysis, Size, Share, Growth and Forecasts to Hexa Research

Ultrasound Device Market - Industry Analysis, Size, Share, Growth and Forecasts to Hexa Research Ultrasound Device Market - Industry Analysis, Size, Share, Growth and Forecasts to 2024 - Hexa Research " The global ultrasound device market was valued at approximately USD 6.8 billion and it is projected

More information

Marketing Health and Nutrition: Does it Work?

Marketing Health and Nutrition: Does it Work? Marketing Health and Nutrition: Does it Work? Julie G. Adams Almond Board of California 14 June 2011 1 Case Study in less than 15 minutes! Why demand creation is a must, not an option, for almonds Capitalizing

More information

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.

MANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr. MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its

More information

Europe Tooth Shade Scanners Industry 2016 Market Research Report

Europe Tooth Shade Scanners Industry 2016 Market Research Report Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Europe Tooth Shade Scanners Industry Market Research Report Europe Tooth Shade Scanners Industry Market Research

More information

Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results

Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall

More information

Financing for Family Planning: Options and Challenges

Financing for Family Planning: Options and Challenges Repositioning Family Planning and Reproductive Health in the region. Financing for Family Planning: Options and Challenges BASINGA Paulin, MD,MSc, PhD Senior Lecturer School of Public Health National University

More information

Committed to Transforming the Treatment Paradigm for Migraine Prevention

Committed to Transforming the Treatment Paradigm for Migraine Prevention June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking

More information

Supplier Code of Business Conduct

Supplier Code of Business Conduct Supplier Code of Business Conduct We act with integrity, honesty and respect. Sempra Energy Values We are an ethical, respectful, high performing, forward looking, responsible partner. Our values define

More information

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics

Liquid Biopsies. Next Generation Cancer Molecular Diagnostics Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology

More information

Flexi-Needles. BMI_FLEXINEEDLES_v2 web

Flexi-Needles. BMI_FLEXINEEDLES_v2 web Flexi-Needles BMI_FLEXINEEDLES_v2 _ _web Best Medical can provide any standard or customized configuration made to your exact specifications, sterile or non-sterile, shipped within 24 hours worldwide!

More information